Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 23598172

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2013 May
First author
Motzer RJ

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Jun;14(7):e254
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet Oncol. 2013 May;14(6):450-1. doi: 10.1016/S1470-2045(13)70119-0.
    note
    Source null
    related pmid
    23598169
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2013 Jun;10(6):305. doi: 10.1038/nrclinonc.2013.74.
    note
    Source null
    related pmid
    23629471
    relationship
    Comment in
  4. citation
    Nat Rev Urol. 2013 Jun;10(6):308. doi: 10.1038/nrurol.2013.100.
    note
    Source null
    related pmid
    23649292
    relationship
    Comment in

Authors and identifiers

  1. name
    Motzer RJ
    type
    Author
  2. name
    Escudier B
    type
    Author
  3. name
    Tomczak P
    type
    Author
  4. name
    Hutson TE
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Negrier S
    type
    Author
  7. name
    Oudard S
    type
    Author
  8. name
    Gore ME
    type
    Author
  9. name
    Tarazi J
    type
    Author
  10. name
    Hariharan S
    type
    Author
  11. name
    Chen C
    type
    Author
  12. name
    Rosbrook B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Motzer RJ
    type
    Author
  2. name
    Escudier B
    type
    Author
  3. name
    Tomczak P
    type
    Author
  4. name
    Hutson TE
    type
    Author
  5. name
    Michaelson MD
    type
    Author
  6. name
    Negrier S
    type
    Author
  7. name
    Oudard S
    type
    Author
  8. name
    Gore ME
    type
    Author
  9. name
    Tarazi J
    type
    Author
  10. name
    Hariharan S
    type
    Author
  11. name
    Chen C
    type
    Author
  12. name
    Rosbrook B
    type
    Author
bibliography ids
  1. nci-bib-88ecc77eb64dea0f45e38f99
book metadata
content sha256
a763486dad0aabe2be526c39443286f248288852199ac1084c117a6b3dd527f5
document type
citation
dois
  1. 10.1016/S1470-2045(13)70093-7
electronic publication date
display
2013 Apr 16
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:23598172
immutable id
pubmed:23598172@a763486dad0aabe2be526c39443286f248288852199ac1084c117a6b3dd527f5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
552-62
volume
14
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Jun;14(7):e254
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet Oncol. 2013 May;14(6):450-1. doi: 10.1016/S1470-2045(13)70119-0.
    note
    Source null
    related pmid
    23598169
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2013 Jun;10(6):305. doi: 10.1038/nrclinonc.2013.74.
    note
    Source null
    related pmid
    23629471
    relationship
    Comment in
  4. citation
    Nat Rev Urol. 2013 Jun;10(6):308. doi: 10.1038/nrurol.2013.100.
    note
    Source null
    related pmid
    23649292
    relationship
    Comment in
outcomes validated
false
pmid
23598172
provenance
batch id
99e008dabc339d38fd44
provider
NCBI PubMed ESummary
record sha256
83e8d2388d144ca32549edf12614562b8d97539ffdfb2804f8fb8eb195a11f6b
response sha256
804916232567480946eda9a00aff276bc44fd9a6d15d9336e773a9c803123d39
retrieved at
2026-09-09T23:46:55.094762+00:00
publication date
display
2013 May
precision
month
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23598172/
title
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Preserved source evidence · Not medical advice